title: Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
abstract: OBJECTIVE
  EMA licensed eribulin mesylate in 2011 for women with advanced breast cancer already treated with at least two lines of chemotherapy, including anthracyclines and taxanes. Azienda Sanitaria Firenze experience is reported to assess the efficacy and safety of eribulin in the real-life setting.
  
  
  METHODS
  Eribulin was infused as per indication. All women treated in the last 2 years were reviewed.
  
  
  RESULTS
  A total of 27 women received eribulin. All but one was pretreated with anthracyclines, 97% with taxanes and 87% with capecitabine. Median age was 63 years (range: 27-80). A median of four cycles of eribulin were infused (range: 2-10). Overall response rate was 30% with a 45% of clinical benefit (response plus stable disease for at least 24 weeks). Toxicities have been as expected. Severe toxicities were rare, with one patient experiencing sepsis and 18% developing grade 3 asthenia.
  
  
  CONCLUSIONS
  Eribulin maintains its activity out of clinical trials, without unexpected toxicities.
authors.affiliation: SOC Oncologia Medica, Dipartimento Oncologico Azienda Sanitaria Firenze, Istituto Toscano Tumori, Piazza Santa Maria Nuova 1, 50100, Firenze, Italia.
authors.forename: Francesca
authors.initials: F
authors.lastname: Martella
authors.affiliation: SOC Oncologia Medica, Dipartimento Oncologico Azienda Sanitaria Firenze, Istituto Toscano Tumori, Piazza Santa Maria Nuova 1, 50100, Firenze, Italia.
authors.forename: Carlotta
authors.initials: C
authors.lastname: Bacci
authors.affiliation: SOC Oncologia Medica, Dipartimento Oncologico Azienda Sanitaria Firenze, Istituto Toscano Tumori, Piazza Santa Maria Nuova 1, 50100, Firenze, Italia.
authors.forename: Clara
authors.initials: C
authors.lastname: Giordano
authors.affiliation: SOC Oncologia Medica, Dipartimento Oncologico Azienda Sanitaria Firenze, Istituto Toscano Tumori, Piazza Santa Maria Nuova 1, 50100, Firenze, Italia.
authors.forename: Francesco
authors.initials: F
authors.lastname: Montagnani
authors.affiliation: Data Manager Clinical Research Group Dipartimento Oncologico Azienda Sanitaria Firenze, Presso Ospedale Santa Maria Annunziata, Via dell'Antella 58, Bagno a Ripoli, Firenze, Italia.
authors.forename: Elena
authors.initials: E
authors.lastname: Gelain
authors.affiliation: Dipartimento del Farmaco Azienda Sanitaria Firenze, Farmacia ospedaliera Ospedale Santa Maria Annunziata, Via dell'Antella 58, Bagno a Ripoli, Firenze, Italia.
authors.forename: Loredana
authors.initials: L
authors.lastname: Rabatti
authors.affiliation: SOC Oncologia Medica, Dipartimento Oncologico Azienda Sanitaria Firenze, Istituto Toscano Tumori, Piazza Santa Maria Nuova 1, 50100, Firenze, Italia.
authors.forename: Luisa
authors.initials: L
authors.lastname: Fioretto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005663:Furans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
keywords: eribulin; metastatic breast cancer; real-life setting